MRD-positive AML Clinical Study

Who May Qualify: - AML (non-M3) compliant with WHO (2016) standards; - In morphological complete remission. - Mrd-positive patients: including bone marrow flow cytometry, PCR quantification of NPM1 mutations, PCR quantification of fusion genes (RUNX 1-RUNX1T1, CBFB-MYH11 and DEK-NUP214), or NGS detection of FLT3 mutation positive. - Age over 14 years old, male or female. willing to sign a consent form must be signed prior to the commencement of all specific study procedures, and for those 14 years of age and older, willing to sign a consent form must be signed by the patient or an immediate family member. Considering the patient's condition, if the patient's signature is not conducive to the treatment of the condition, the willing to sign a consent form shall be signed by the legal guardian or the patient's immediate family. Who Should NOT Join This Trial: - Patients who intend to undergo hematopoietic stem cell transplantation within 4 weeks - The diagnosis is APL - Those who were not considered suitable for inclusion by the researchers. Always talk to your doctor about whether this trial is right for you.